BUD13 Inhibitors

BUD13 inhibitors are a class of chemical compounds designed to modulate or interfere with processes related to pre-mRNA splicing indirectly. These inhibitors primarily target key components of the spliceosome machinery and other splicing-related pathways, affecting BUD13's role in splicing regulation. Several compounds within this category, such as Spliceostatin A, Pladienolide B, and E7107, exhibit inhibitory properties against spliceosome assembly and function. By disrupting the spliceosome, these compounds can influence splice site recognition, leading to altered splicing events that may indirectly impact BUD13's involvement in splicing regulation. Additionally, Meayamycin B and H3B-8800, both SF3b complex inhibitors, can further hinder spliceosome assembly, affecting BUD13's stabilization of interactions within the spliceosome, thus influencing the accuracy and efficiency of splicing.

Furthermore, FR901464 has been recognized for their ability to interfere with spliceosome assembly and function. These compounds can lead to aberrant splicing patterns, indirectly affecting BUD13's role in maintaining splicing fidelity. TG003, a CDK7 inhibitor, can influence RNA splicing by targeting RNA polymerase II phosphorylation, which may indirectly impact BUD13's function. Rocaglamide, through its effects on splicing factors, and Cisplatin, which can modulate DNA structure affecting transcription factors, can indirectly influence BUD13 and its role in pre-mRNA splicing. Actinomycin D, by interfering with transcription, can indirectly impact pre-mRNA levels and splicing, affecting BUD13's function in splicing regulation. Finally, Camptothecin, which targets topoisomerase I, may indirectly affect DNA relaxation during transcription, subsequently influencing splicing processes and BUD13. Overall, BUD13 inhibitors constitute a diverse group of compounds that can disrupt splicing-related pathways and processes, indirectly influencing the function of BUD13 in pre-mRNA splicing regulation.